Kura Oncology Reveals New Data on Darlifarnib and Cabozantinib Combination Therapy Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KURA?
Source: Newsfilter
- Clinical Data Highlights: In the FIT-001 clinical trial, the combination of darlifarnib and cabozantinib demonstrated a 44% objective response rate (ORR) and a 94% disease control rate (DCR) in clear cell renal cell carcinoma (ccRCC) patients previously treated with cabozantinib, indicating significant antitumor activity in refractory patients.
- Tumor Shrinkage Effects: Among treated patients, 75% experienced tumor shrinkage, with reductions ranging from 32% to 47%, showcasing the efficacy of this treatment regimen particularly in heavily pretreated patients who had stable disease on prior cabozantinib therapy.
- Good Tolerability: All renal cell carcinoma patients across various doses of cabozantinib exhibited a manageable safety and tolerability profile, with treatment durations reaching up to 56 weeks, further validating the clinical applicability of this combination.
- Future Outlook: Kura Oncology plans to further evaluate the darlifarnib and cabozantinib combination therapy in subsequent studies, aiming to provide more effective treatment options for renal cell carcinoma patients, especially in settings where existing therapies are limited.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KURA
Wall Street analysts forecast KURA stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.050
Low
16.00
Averages
29.71
High
40.00
Current: 9.050
Low
16.00
Averages
29.71
High
40.00
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kura Oncology Reveals New Data on Darlifarnib and Cabozantinib Combination Therapy Potential
- Clinical Data Highlights: In the FIT-001 clinical trial, the combination of darlifarnib and cabozantinib demonstrated a 44% objective response rate (ORR) and a 94% disease control rate (DCR) in clear cell renal cell carcinoma (ccRCC) patients previously treated with cabozantinib, indicating significant antitumor activity in refractory patients.
- Tumor Shrinkage Effects: Among treated patients, 75% experienced tumor shrinkage, with reductions ranging from 32% to 47%, showcasing the efficacy of this treatment regimen particularly in heavily pretreated patients who had stable disease on prior cabozantinib therapy.
- Good Tolerability: All renal cell carcinoma patients across various doses of cabozantinib exhibited a manageable safety and tolerability profile, with treatment durations reaching up to 56 weeks, further validating the clinical applicability of this combination.
- Future Outlook: Kura Oncology plans to further evaluate the darlifarnib and cabozantinib combination therapy in subsequent studies, aiming to provide more effective treatment options for renal cell carcinoma patients, especially in settings where existing therapies are limited.
See More
Kura Oncology Presents Darlifarnib Clinical Data at IKCS Europe 2026
- Clinical Trial Update: Kura Oncology will present updated data from the FIT-001 clinical trial on April 17, 2026, at the International Kidney Cancer Symposium, evaluating the efficacy of darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, indicating potential improvements in patient treatment outcomes.
- Efficacy and Safety: The combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile at the 2025 ESMO Congress, suggesting its potential as a new treatment option for patients with advanced renal cell carcinoma.
- Virtual Investor Call: Kura will host a virtual investor call on April 17, 2026, featuring management and clinical investigators discussing the latest developments in the darlifarnib program, which may enhance investor confidence in the company's future growth.
- Drug Mechanism: Darlifarnib, a next-generation farnesyl transferase inhibitor, is designed to inhibit the farnesylation of RHEB, thereby enhancing the activity of multiple targeted therapies, including VEGFR-targeted therapies, potentially offering more effective treatment options for renal cancer patients.
See More
Kura Oncology Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Kura Oncology granted 153,750 nonstatutory stock options to six new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $8.34 per share, matching the closing price on the grant date, which serves to incentivize employees to grow alongside the company.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring that new employees maintain their service relationship during the vesting period to enhance long-term commitment.
- Strategic Positioning: Kura Oncology focuses on precision medicine, committed to developing innovative drugs targeting cancer, particularly in hematologic malignancies and solid tumors, continuously enhancing the company's competitiveness in the biopharmaceutical industry.
See More
KURA ONCOLOGY INC: MIZUHO LOWERS TARGET PRICE FROM $30 TO $25
- Company Announcement: Kura Oncology has announced a reduction in the target price for its stock from $30 to $25.
- Market Impact: This adjustment may influence investor sentiment and trading activity related to Kura Oncology's shares.
See More
Kura Oncology Grants Stock Options to New Employees
- Stock Option Grant: On March 2, 2026, Kura Oncology granted 44,700 nonstatutory stock options to four new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $8.68 per share, equal to the closing price on the grant date, a strategy that aligns employee interests with those of shareholders.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring continued contributions from new employees during their tenure.
- Strategic Positioning: Kura Oncology focuses on precision medicine, committed to developing innovative drugs targeting cancer, particularly in hematologic malignancies and solid tumors, showcasing its long-term growth potential in the biopharmaceutical sector.
See More
Kura Oncology Reports Q4 2025 Earnings with KOMZIFTI Launch Success
- FDA Approval and Product Launch: Kura Oncology achieved FDA approval for KOMZIFTI in 2025 and successfully initiated its commercial launch, generating $2.1 million in net product revenue within weeks, marking a significant advancement in the treatment of acute myeloid leukemia (AML).
- Market Opportunity and Strategic Expansion: The total U.S. market opportunity for KOMZIFTI is estimated at approximately $7 billion, with Kura planning to expand its use into frontline AML and combination therapies, demonstrating the company's ambition for market leadership.
- Strong Insurance Coverage and Market Feedback: 84% of private payers established coverage for KOMZIFTI within 90 days of approval, with some requiring patients to use it before competitors, further validating its competitive advantage in the market.
- Financial Performance and Future Outlook: In Q4 2025, Kura reported collaboration revenue of $15.2 million, with expectations for collaboration revenue to reach $45 million to $55 million in 2026, reflecting the company's confidence in driving revenue growth and market share.
See More
Kura Oncology Reveals New Data on Darlifarnib and Cabozantinib Combination Therapy Potential
- Clinical Data Highlights: In the FIT-001 clinical trial, the combination of darlifarnib and cabozantinib demonstrated a 44% objective response rate (ORR) and a 94% disease control rate (DCR) in clear cell renal cell carcinoma (ccRCC) patients previously treated with cabozantinib, indicating significant antitumor activity in refractory patients.
- Tumor Shrinkage Effects: Among treated patients, 75% experienced tumor shrinkage, with reductions ranging from 32% to 47%, showcasing the efficacy of this treatment regimen particularly in heavily pretreated patients who had stable disease on prior cabozantinib therapy.
- Good Tolerability: All renal cell carcinoma patients across various doses of cabozantinib exhibited a manageable safety and tolerability profile, with treatment durations reaching up to 56 weeks, further validating the clinical applicability of this combination.
- Future Outlook: Kura Oncology plans to further evaluate the darlifarnib and cabozantinib combination therapy in subsequent studies, aiming to provide more effective treatment options for renal cell carcinoma patients, especially in settings where existing therapies are limited.
See More
Kura Oncology Presents Darlifarnib Clinical Data at IKCS Europe 2026
- Clinical Trial Update: Kura Oncology will present updated data from the FIT-001 clinical trial on April 17, 2026, at the International Kidney Cancer Symposium, evaluating the efficacy of darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, indicating potential improvements in patient treatment outcomes.
- Efficacy and Safety: The combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile at the 2025 ESMO Congress, suggesting its potential as a new treatment option for patients with advanced renal cell carcinoma.
- Virtual Investor Call: Kura will host a virtual investor call on April 17, 2026, featuring management and clinical investigators discussing the latest developments in the darlifarnib program, which may enhance investor confidence in the company's future growth.
- Drug Mechanism: Darlifarnib, a next-generation farnesyl transferase inhibitor, is designed to inhibit the farnesylation of RHEB, thereby enhancing the activity of multiple targeted therapies, including VEGFR-targeted therapies, potentially offering more effective treatment options for renal cancer patients.
See More
Kura Oncology Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Kura Oncology granted 153,750 nonstatutory stock options to six new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $8.34 per share, matching the closing price on the grant date, which serves to incentivize employees to grow alongside the company.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring that new employees maintain their service relationship during the vesting period to enhance long-term commitment.
- Strategic Positioning: Kura Oncology focuses on precision medicine, committed to developing innovative drugs targeting cancer, particularly in hematologic malignancies and solid tumors, continuously enhancing the company's competitiveness in the biopharmaceutical industry.
See More
KURA ONCOLOGY INC: MIZUHO LOWERS TARGET PRICE FROM $30 TO $25
- Company Announcement: Kura Oncology has announced a reduction in the target price for its stock from $30 to $25.
- Market Impact: This adjustment may influence investor sentiment and trading activity related to Kura Oncology's shares.
See More
Kura Oncology Grants Stock Options to New Employees
- Stock Option Grant: On March 2, 2026, Kura Oncology granted 44,700 nonstatutory stock options to four new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $8.68 per share, equal to the closing price on the grant date, a strategy that aligns employee interests with those of shareholders.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring continued contributions from new employees during their tenure.
- Strategic Positioning: Kura Oncology focuses on precision medicine, committed to developing innovative drugs targeting cancer, particularly in hematologic malignancies and solid tumors, showcasing its long-term growth potential in the biopharmaceutical sector.
See More
Kura Oncology Reports Q4 2025 Earnings with KOMZIFTI Launch Success
- FDA Approval and Product Launch: Kura Oncology achieved FDA approval for KOMZIFTI in 2025 and successfully initiated its commercial launch, generating $2.1 million in net product revenue within weeks, marking a significant advancement in the treatment of acute myeloid leukemia (AML).
- Market Opportunity and Strategic Expansion: The total U.S. market opportunity for KOMZIFTI is estimated at approximately $7 billion, with Kura planning to expand its use into frontline AML and combination therapies, demonstrating the company's ambition for market leadership.
- Strong Insurance Coverage and Market Feedback: 84% of private payers established coverage for KOMZIFTI within 90 days of approval, with some requiring patients to use it before competitors, further validating its competitive advantage in the market.
- Financial Performance and Future Outlook: In Q4 2025, Kura reported collaboration revenue of $15.2 million, with expectations for collaboration revenue to reach $45 million to $55 million in 2026, reflecting the company's confidence in driving revenue growth and market share.
See More
